SCHEMBL1748867

SCHEMBL1748867

COc1cc2c(-c3cc4cccnc4n3S(=O)(=O)c3ccc(C)cc3)cn(C)c2cc1OCCN1CCC(O)CC1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.39
ADRA1A P35348 4/20 0.38
ADRA1B P35368 4/20 0.38
PDGFRB P09619 1/20 0.36
CSF1R P07333 1/20 0.35
CCNE1 P24864 2/20 0.35
CDK2 P24941 2/20 0.35
ATM Q13315 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KDR P35968 1/20 0.34
MET P08581 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
HTR1A P08908 1/20 0.34
HTR7 P34969 1/20 0.34
CRHR1 P34998 1/20 0.34
FGFR1 P11362 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1748711 0.90 KMT2A (0.40) IGF1RKDR
SCHEMBL1748634 0.87 IGF1R (0.44) IGF1RCCNE1CDK2L3MBTL1PTGDR2
SCHEMBL1749119 0.87 IGF1R (0.44) IGF1RCCNE1CDK2ATML3MBTL1
SCHEMBL1778785 0.86 IGF1R (0.50) IGF1RCCNE1CDK2L3MBTL1PTGDR2
SCHEMBL5798572 0.86 MET (0.39) IGF1RADRA1AADRA1BPDGFRBCSF1R
SCHEMBL1749000 0.86 IGF1R (0.44) IGF1RCCNE1CDK2L3MBTL1PTGDR2
SCHEMBL1748899 0.86 IGF1R (0.44) IGF1RCCNE1CDK2L3MBTL1PTGDR2
SCHEMBL1749120 0.86 IGF1R (0.44) IGF1RCCNE1CDK2L3MBTL1PTGDR2
SCHEMBL1748833 0.85 IGF1R (0.42) IGF1RCCNE1CDK2L3MBTL1PTGDR2
SCHEMBL1749102 0.84 IGF1R (0.42) IGF1RCCNE1CDK2L3MBTL1PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968566-B2 Pyrrolo(2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2011-06-28 US disclosed
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2009-09-17 US disclosed
US-7528147-B2 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2009-05-05 US disclosed
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2007-04-26 US disclosed
EP-1732546-A2 NOVEL PYRROLO (2,3-B)PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS Aventis Pharma S.A. (FR) 2006-12-20 EP disclosed
WO-2005095399-A2 NOVEL PYRROLO (2,3-B)PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2005-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS MAP3K19, MAP4K2, MAP3K1 IGF1R 817/4885ADRA1A 1791/4885ADRA1B 1090/4885
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors MAP3K19, MAP4K2, MAP3K1 IGF1R 817/4885ADRA1A 1791/4885ADRA1B 1090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.